Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $2.4 million.

  • Biofrontera's Other Operating Expenses fell 51.52% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year decrease of 20.49%. This contributed to the annual value of $36.2 million for FY2024, which is 5.29% down from last year.
  • Latest data reveals that Biofrontera reported Other Operating Expenses of $2.4 million as of Q3 2025, which was down 12.76% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Other Operating Expenses peaked at $25.8 million during Q4 2023, and registered a low of $196,000 during Q3 2022.
  • Its 3-year average for Other Operating Expenses is $7.5 million, with a median of $4.4 million in 2024.
  • Per our database at Business Quant, Biofrontera's Other Operating Expenses crashed by 93.78% in 2022 and then surged by 2,381.63% in 2023.
  • Biofrontera's Other Operating Expenses (Quarterly) stood at $1.9 million in 2021, then surged by 206.86% to $5.7 million in 2022, then skyrocketed by 354.69% to $25.8 million in 2023, then decreased by 11.68% to $22.8 million in 2024, then plummeted by 51.52% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.7 million for Q2 2025, and $3.3 million during Q1 2025.